DNTH · Dianthus Therapeutics

The thesis

Dianthus Therapeutics' shares are more likely to lag the S&P 500 than lead it over the next three months. The case rests on the Phase 2 MoMeNtum trial of claseprubart in multifocal motor neuropathy (MMN), which the company guided to top-line results in December 2026 in its 4 November 2026 third-quarter release. The randomized result settles the call.

The shares closed at $89.30 on 11 November 2026, 24.2% below the intraday 52-week high of $117.88 set on 19 August 2026. The three-month price change is −18.5%, measured against a close of $109.60 on 13 August 2026. The price already carries some doubt about the readout, but it still sits well above the $35.50 closing low of 13 November 2025, so a positive result is partly expected and a miss has far to fall.

The company also set a 2027 Phase 3 start in MMN if the data support it (release, 4 November 2026). The shares have recovered from the $83.01 close of 5 November 2026 and have closed between $86.03 and $90.00 in the four sessions since.

Bullish and bearish views on Dianthus Therapeutics, Inc.

The bull case on Dianthus Therapeutics, Inc. (DNTH), in brief: a dated randomized readout is close. The bear case: controlled evidence does not yet exist.

Bull case

• A dated randomized readout is close. Dianthus guided MoMeNtum top-line results to December 2026 and a Phase 3 MMN trial in 2027 (company release, 4 November 2026). A positive randomized result would be the first controlled evidence for claseprubart.
• Enrollment exceeded the original plan. The company's second-quarter 2026 update said MoMeNtum enrolled above its original 36-patient target, with top-line results from 46 patients on track for December 2026.
• Cash covers the guided calendar. Dianthus reported about $1.2 billion in cash and investments at the end of the third quarter and a runway into 2030 (company release, 4 November 2026).
• Pivotal timelines are dated. The Phase 3 CAPTIVATE trial in chronic inflammatory demyelinating polyneuropathy (CIDP) now needs fewer than 200 patients in Part A, with Part A results by end-2027 and Part B by end-2028. Phase 3 EMERGE in generalized myasthenia gravis reports in the second half of 2028 (company release, 4 November 2026).
• Losses narrowed. Third-quarter loss per share was $0.81 against $0.97 a year earlier (company results, 4 November 2026).

Bear case

• Controlled evidence does not yet exist. The 75% response rate among the first 40 CAPTIVATE Part A completers (company filing, 12 June 2026) came without a control arm. MoMeNtum is the first randomized test, and a missed primary endpoint would weigh on views of the CIDP and myasthenia gravis programs that share the molecule.
• Stock-sale capacity is open. Dianthus filed an automatic registration statement (Form S-3ASR) on 18 September 2026 covering up to $500 million of common stock. Registration alone does not show that shares were sold, and the 4 November 2026 release reported no sales.
• Insiders sold after the August high. SEC Form 4 filings show a director's sale of 2,778 shares at $117.55 on 19 August 2026, an executive vice president's sale of 23,124 shares at an average $106.41 on 1 September 2026, and the chief accounting officer's sale of 20,000 shares at an average $101.38 on 17 September 2026. All three followed option exercises under Rule 10b5-1 pre-arranged plans, and three transactions are too few to support a conclusion.
• The wait for pivotal data is long. CAPTIVATE Part B is guided to end-2028 and EMERGE to the second half of 2028, so MoMeNtum is the only near-term clinical datapoint.
• The readout sits inside the window. A December result falls within the next 63 trading sessions, so a mixed or negative result would hit the shares before any later data can offset it.

Price setup

The shares closed at $89.30 on 11 November 2026. That is level with the 50-day average of $89.05 and above the 200-day average of $86.52 (both from adjusted daily closes). The closes since 4 November 2026 were $85.81, $83.01, $86.03, $90.00, $88.81 and $89.30.

The 52-week high is $117.88, set intraday on 19 August 2026, the same day as the director's sale at $117.55. The August and early-September range, when the shares closed near $106 around 1 September 2026, remains well above the current price.

The 52-week closing low is $35.50, on 13 November 2025. The shares have moved from there to a level that already reflects substantial confidence in claseprubart.

Catalysts ahead

• December 2026 (est.): MoMeNtum Phase 2 top-line data for claseprubart in multifocal motor neuropathy, guided to December 2026. A randomized result tests whether claseprubart efficacy extends beyond open-label observations and decides the 2027 Phase 3 plan.
• 2027 (est.): Planned Phase 3 start in multifocal motor neuropathy. Depends on a supportive MoMeNtum result and sets the next dated step for the program.

What would change the view

A daily close above $102.69, 15% over the 11 November 2026 close, which would show the shares leading the S&P 500. Positive MoMeNtum top-line data with a clear primary-endpoint win in December 2026 would also show the shares leading.

What it trades with

Dianthus trades on its own clinical calendar. Single-asset biotech shares with a pending randomized readout often move with the small- and mid-cap biotech group, which tracks risk appetite. Class-wide data from other complement-pathway and neuromuscular antibody programs can also move the shares. No correlation figure is stated because the price history holds too few comparable readout windows to measure one.